102,662 Shares in Becton, Dickinson and Company $BDX Purchased by Nykredit A S

Nykredit A S acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 102,662 shares of the medical instruments supplier’s stock, valued at approximately $15,536,000.

Other hedge funds also recently bought and sold shares of the company. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at approximately $25,000. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $26,000. Meeder Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares in the last quarter. Main Street Group LTD purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at about $29,000. Finally, Bell Investment Advisors Inc acquired a new position in Becton, Dickinson and Company in the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. The Goldman Sachs Group reduced their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Royal Bank Of Canada upped their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target for the company. Finally, Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $187.67.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $184.78 on Friday. The business has a 50-day simple moving average of $170.05 and a 200-day simple moving average of $160.69. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company has a market cap of $50.91 billion, a PE ratio of 55.66, a P/E/G ratio of 13.22 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the firm posted $3.68 earnings per share. The company’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 9,105 shares of company stock worth $1,590,208 over the last 90 days. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.